publication . Article . 2011

Chemotherapy Definitions and Policies for Thymic Malignancies

Patrick J. Loehrer; Nicolas Girard; Rohit Lal; Heather A. Wakelee; Gregory J. Riely;
Open Access
  • Published: 01 Jan 2011 Journal: Journal of Thoracic Oncology, volume 6, pages S1749-S1755 (issn: 1556-0864, Copyright policy)
  • Publisher: Elsevier BV
  • Country: France
Abstract
Thymic malignancies are rare epithelial tumors that may be aggressive and difficult to treat.1 Thymomas are usually localized to the anterior mediastinum and are frequently eligible for upfront surgical resection, which is the mainstay of the curative-intent treatment.1 However, approximately 30% of patients present with an advanced tumor at the time of diagnosis, with invasion of neighboring organs, dissemination to the pleura, the pericardium, or less frequently extrathoracic organs. In such cases, chemotherapy has been used both to reduce the tumor burden—possibly allowing subsequent surgery or radiotherapy—and to achieve prolonged disease control. Recurrence...
Subjects
free text keywords: Oncology, Pulmonary and Respiratory Medicine, Radiotherapy, Thymic hyperplasia, Corticosteroids, antineopolastic agent, therapeutic use, thymona, corticostreroid, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Lung neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, medicine.medical_specialty, medicine, Chemotherapy, medicine.medical_treatment, Systemic therapy, Thymoma, medicine.disease, Myasthenia gravis, Disease, Thymic carcinoma, business.industry, business, Radiation therapy, Internal medicine, Octreotide, medicine.drug
Any information missing or wrong?Report an Issue